Inhibition of ABL tyrosine kinase potentiates radiation-induced terminal growth arrest in anaplastic thyroid cancer cells

Radiation Research

Volumn 165, Issue 1, 2006, Pages 35-42

  Podtcheko, A ^a   Ohtsuru, A ^a,b   Namba, H ^a   Saenko, V ^a   Starenki, D ^a   Palona, I ^a   Sedliarou, I ^a   Rogounovitch, T ^a   Yamashita, S ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BETA GALACTOSIDASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; SENESCENCE ASSOCIATED BETA GALACTOSIDASE; UNCLASSIFIED DRUG;

ADOLESCENT; ANAPLASTIC CARCINOMA; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN ARO; CELL STRAIN FRO; COLONY FORMATION; CONTROLLED STUDY; CYTOCHEMISTRY; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; IRRADIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RADIATION RESPONSE; RADIOSENSITIZATION; SENESCENCE; THYROID CANCER; THYROID UNDIFFERENTIATED CARCINOMA; TUMOR XENOGRAFT; WESTERN BLOTTING;

APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RADIATION DOSAGE; RADIATION TOLERANCE; THYROID NEOPLASMS;

ANIMALIA;

EID: 29644434934     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR3466.1     Document Type: Article

References (27)

1. P. E. Goretzki, D. Simon, A. Frilling, J. Witte, G. Reiners, M. Grussendorf, F. A. Horster and H. D. Roher, Surgical reintervention for differentiated thyroid cancer. Br. J. Surg. 80, 1009-1012 (1993).
2. D. E. Heron, S. Karimpour and P. W. Grigsby, Anaplastic thyroid carcinoma: Comparison of conventional radiotherapy and hyperfractionation chemoradiotherapy in two groups. Am. J. Clin. Oncol. 25, 442-446 (2002).
3. G. W. Krystal, S. Honsawek, J. Litz and E. Buchdunger, The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin. Cancer Res. 6, 3319-3326 (2000).
4. L. Zhou, N. An, R. C. Haydon, Q. Zhou, H. Cheng, Y. Peng, W. H. H. Jiang Luu, P. Vanichakarn, J. P. Szatkowski and T. C. He, Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity. Cancer Lett 193, 161-170 (2003).
5. T. Tauchi, A. Nakajima, G. Sashida, T. Shimamoto, J. H. Ohyashiki, K. Abe, K. Yamamoto and K. Ohyashiki, Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. Clin. Cancer Res. 8, 3341-3347 (2002).
6. J. S. Russell, K. Brady, W. E. Burgan, M. A. Cerra, K. A. Oswald, K. Camphausen and P. J. Tofilon, Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res. 63, 7377-7383 (2003).
7. B. J. Druker, Imatinib alone and in combination for chronic myeloid leukemia. Semin. Hematol. 40, 50-58 (2003).
8. T. Sjoblom, A. Shimizu, K. P. O'Brien, K. Pietras, P. Dal Cin, E. Buchdunger, J. P. Dumanski, A. Ostman and C. H. Heldin, Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 61, 5778-5783 (2001).
9. G. Bellone, D. Ferrero, A. Carbone, M. R. De Quadros, C. Gramigni, A. Prati, W. Davidson, P. Mioli, L. Dughera and U. Rodeck, Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI571. Cancer Biol. Ther. 3, 385-392 (2004).
10. S. M. Apte, D. Fan, J. J. Killion and I. J. Fidler, Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin. Cancer Res. 10, 897-908 (2004).
11. K. Pietras, M. Stumm, M. Hubert, E. Buchdunger, K. Rubin, C. H. Heldin, P. McSheehy, M. Wartmann and A. Ostman, STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin. Cancer Res. 9, 3779-3787 (2003).
12. N. Uemura and J. D. Griffin, The ABL kinase inhibitor STI571 does not affect survival of hematopoietic cells after ionizing radiation. Blood 96, 3294-3295 (2000).
13. S. Dan, M. Naito, H. Seimiya, A. Kizaki, T. Mashima and T. Tsuruo, Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells. Oncogene 18, 1277-1283 (1999).
14. P. Zhang, W. Y. Gao, S. Turner and B. S. Ducatman, Gleevec (STI571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol. Cancer 2, 1 (2003).
15. A. Podtcheko, A. Ohtsuru, S. Tsuda, H. Namba, V. Saenko, M. Nakashima, N. Mitsutake, S. Kanda, J. Kurebayashi and S. Yamashita, The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J. Clin. Endocrinol. Metab. 88, 1889-1896 (2003).
16. L. Cheng, R. V. Lloyd, A. L. Weaver, T. M. Pisansky, J. C. Cheville, D. M. Ramnani, B. C. Leibovich, M. L. Blute, H. Zincke and D. G. Bostwick, The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin. Cancer Res. 6, 1896-1899 (2000).
17. U. Raju, E. Nakata, P. Yang, R. A. Newman, K. K. Ang and L. Milas, In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: Mechanistic considerations. Int. J. Radiat. Oncol. Biol. Phys. 54, 886-894 (2002).
18. B. D. Chang, Y. Xuan, E. V. Broude, H. Zhu, B. Schott, J. Fang and I. B. Roninson, Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 18, 4808-4818 (1999).
19. G. P. Dimri, X. Lee, G. Basile, M. Acosta, G. Scott, C. Roskelley, E. E. Medrano, M. Linskens, I. Rubelj and O. Pereira-Smith, A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 92, 9363-9367 (1995).
20. S. Kharbanda, R. Ren, P. Pandey, T. D. Shafman, S. M. Feller, R. R. Weichselbaum and D. W. Kufe, Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 376, 785-788 (1995).
21. J. G. Gong, A. Costanzo, H. Q. Yang, G. Melino, W. G. Kaelin, Jr., M. Levrero and J. Y. Wang, The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399, 806-809 (1999).
22. B. B. Brasher and R. A. Van Etten, c-ABL has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J. Biol. Chem 275, 35631-35637 (2002).
23. A. Podtcheko, H. Namba, V. Saenko, A. Ohtsuru, D. Starenki, S. Meirmanov, I. Polona, T. Rogounovitch and S. Yamashita, Radiation induces senescent-like terminal growth arrest in thyroid cell lines. Thyroid 15, 306-313 (2005).
24. R. H. te Poele, A. L. Okorokov, L. Jardine, J. Cummings and S. P. Joel, DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 62, 1876-1883 (2002).
25. I. B. Roninson, E. V. Broude and B. D. Chang, If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist. Updat. 5, 303-313 (2001).
26. H. Namba, T. Hara, T. Tukazaki, K. Migita, N. Ishikawa, K. Ito, S. Nagataki and S. Yamashita, Radiation-induced G1 arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells. Cancer Res. 55, 2075-2080 (1995).
27. H. Kantarjian, M. Talpaz, S. O'Brien, G. Garcia-Manero, S. Verstovsek, F. Giles, M. B. Rios, J. Shan, L. Letvak and J. Cortes, High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 8, 2873-2878 (2004).